Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

BIRMINGHAM, Ala., Oct. 20 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) and partner Shionogi & Co., Ltd. (Shionogi) today announced that positive Phase 2 data on peramivir, a potent neuraminidase inhibitor for the treatment of influenza, has been accepted as a late-breaker poster at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/ Infectious Diseases Society of America (IDSA) 46th annual meeting taking place from October 25 to October 28 in Washington, D.C. The study was conducted by BioCryst's development partner, Shionogi.

The poster titled, "A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients" (Poster Session # 302: Respiratory Viruses I: Influenza and RSV) will be presented on Tuesday, October 28 from 12:15 p.m. - 1:15 p.m. Eastern Time in Hall C by Dr. Shigeru Kohno, Dean, Nagasaki University Graduate School of Medicine and Professor, Infection Immunology Department, Nagasaki University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

About Peramivir

Peramivir is an antiviral agent that inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against viral strains that are resistant to currently available treatments and has been safely administered to healthy subjects at high dose levels. Peramivir is currently being studied in hospitalized and outpatient flu, utilizing either an intramuscular or intravenous formulation. BioCryst is currently conducting two Phase 2 studies with peramivir, a study in subjects with acute, uncomplicated influenza, and a study in subjects with acute se
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pittcon is pleased to announce that ... Matsuda, Horiba Scientific, have organized a session on nanotechnology ... JASIS , Asia’s largest analytical and scientific instruments show, ... Japan. , The four speakers in this U.S. ... Molecules to Single Cells” will present their use of ...
(Date:8/29/2014)... Livermore, California (PRWEB) August 29, 2014 ... Department of Energy's 2014 Hydrogen Production R&D ... photoelectrochemically -- by splitting water using sunlight. , ... Laboratory (NREL) and the University of Nevada, Las ... its work developing models of photoelectrochemical solar-hydrogen production ...
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... Best Sanitizers, Inc., the first company to ... asks food processors and food handling professionals to prepare ... currently using to Best Sanitizers’ Alpet® E3 Plus ... fighting cross-contamination and the spread of pathogens in the ... key criteria that make a hand sanitizer most effective, ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... Databases ... Receptors and Proteases, PARIS, August 18 Aureus ... life sciences discovery,announced today the release of three new ... for the important,drug targets Nuclear Receptor and Protease, as ...
... Aug. 18 LifeVantage Corporation,(OTC Bulletin Board: LFVN), the ... the progressive rate of aging, today announced,that the company,s ... interview on WallSt.net,s 3-Minute Press Show., The interview ... of the company,s latest press release., ...
... Inc. (OTC Bulletin Board: YGYB) ("Yongye" or the "Company"),a ... and,animals in the People,s Republic of China, today announced ... Second Quarter 2008 Highlights -- Revenue ... second quarter of 2007, and ...
Cached Biology Technology:Aureus Pharma Releases New Unified Knowledge Database 2[video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.net's 3-Minute Press Show 2Yongye Biotechnology International Announces Second Quarter Results 2Yongye Biotechnology International Announces Second Quarter Results 3Yongye Biotechnology International Announces Second Quarter Results 4Yongye Biotechnology International Announces Second Quarter Results 5Yongye Biotechnology International Announces Second Quarter Results 6Yongye Biotechnology International Announces Second Quarter Results 7Yongye Biotechnology International Announces Second Quarter Results 8Yongye Biotechnology International Announces Second Quarter Results 9Yongye Biotechnology International Announces Second Quarter Results 10Yongye Biotechnology International Announces Second Quarter Results 11
(Date:9/1/2014)... 1, 2014, 10:20 AM EDT) It may be ... foods over unhealthy higher-calorie foods, according to new research ... Research Center on Aging (USDA HNRCA) at Tufts University ... the journal Nutrition & Diabetes , a brain ... it is possible to reverse the addictive power of ...
(Date:9/1/2014)... WASHINGTON About 50 years ago, electron microscopy revealed ... cells, move around and disappear. But scientists still don,t ... cloud-like collections of proteins are believed to be crucial ... offer a new approach to disease treatment., In the ... issuing a call to investigators from various backgrounds, from ...
(Date:9/1/2014)... week-long discussions and decisions of the Nomenclature Section of ... Australia in July 2011. This meeting is held every ... experts on the rules for naming algae, fungi and ... book for naming the organisms they study. This is ... of Nomenclature for algae, fungi, and plants, which was ...
Breaking Biology News(10 mins):Training your brain to prefer healthy foods 2Scientists call for investigation of mysterious cloud-like collections in cells 2Week-long meeting on naming algae, fungi, and plants recorded for posterity 2
... the Johns Hopkins School of Medicine and their colleagues have ... addition to their own can acquire new color vision, a ... new sensory information than anticipated. , This work, appearing ... ancestral primate inherited a new type of photoreceptor more than ...
... aren't as busy as, well, a bee. It all ... that a key to the insects' success in adapting to ... temperatures when flying to flowers. Whether and how they ... from the University of Washington and the University of Puget ...
... Schulich School of Medicine & Dentistry at The University ... Edinburgh, have discovered a way to kill the cystic ... of Dr. Miguel Valvano, Department of Microbiology and Immunology, ... of the Journal of Bacteriology, and highlighted in Nature ...
Cached Biology News:Making mice with enhanced color vision 2Making mice with enhanced color vision 3Bumblebee house warming -- it takes a village 2Bumblebee house warming -- it takes a village 3Key found to kill cystic fibrosis superbug 2
Form: Ready to use Applications: ELISA...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Defender against cell death 1...
Biology Products: